A 19-year-old woman presents to the dermatology clinic for a follow-up of worsening acne. She has previously tried topical tretinoin as well as topical and oral antibiotics with no improvement. She recently moved to the area for college and says the acne has caused significant emotional distress when it comes to making new friends. She has no significant past medical or surgical history. Family and social history are also noncontributory. The patient’s blood pressure is 118/77 mm Hg, the pulse is 76/min, the respiratory rate is 17/min, and the temperature is 36.6°C (97.9°F). Physical examination reveals erythematous skin lesions including both open and closed comedones with inflammatory lesions overlying her face, neck, and upper back. The patient asks about oral isotretinoin. Which of the following is the most important step in counseling this patient prior to prescribing oral isotretinoin?

Document 2 negative urine or blood pregnancy tests before beginning oral isotretinoin

Wear a wide-brimmed hat outdoors

Apply topical retinoids in the evening before bed

Use non-comedogenic sunscreen daily with SPF of at least 45

Avoid direct sunlight, from 10am to 2pm

False about melasma is?

Hydroquinone has role in the treatment

Commonly affects sun-exposed areas

Oral contraceptives can induce it

Agents for Pigmentary Disorders for FMGE: High-Yield Pharmacology Lessons

Agents for Pigmentary Disorders - Melanin Maze

Melanogenesis Pathway:
- Melanocytes synthesize melanin within melanosomes. UV exposure is a key trigger.
- Tyrosinase: Copper-containing, rate-limiting enzyme converting tyrosine to melanin.
Pigmentary Disorders Classification:
- Hyperpigmentation (↑ melanin production/deposition):
  - Melasma (patches on sun-exposed areas)
  - Post-Inflammatory Hyperpigmentation (PIH)
  - Lentigines (age/sun spots)
- Hypo/Depigmentation (↓/absent melanin):
  - Vitiligo (melanocyte destruction)
  - Albinism (genetic defect in melanin synthesis)
  - Pityriasis alba (hypopigmented patches)

⭐ Tyrosinase is a copper-containing enzyme crucial for melanin synthesis; its inhibition is a primary target for many skin-lightening agents.

Agents for Pigmentary Disorders - Shade Shifters

Clinical presentation of melasma Targets hyperpigmentation by reducing melanin.

Hydroquinone (HQ)
- MOA: Competitive tyrosinase inhibition; melanocytotoxic.
- Conc: 2-4%.
- SEs: Irritation, contact dermatitis, paradoxical post-inflammatory hyperpigmentation, exogenous ochronosis (📌 'HQ OCH!').
Azelaic Acid
- MOA: Tyrosinase inhibition; anti-inflammatory, antibacterial, comedolytic.
- Safe in pregnancy.
Kojic Acid, Arbutin
- MOA: Tyrosinase inhibition.
Topical Retinoids (e.g., Tretinoin, Adapalene)
- MOA: ↑ Epidermal cell turnover, ↓ melanosome transfer, weak tyrosinase inhibition.
- SEs: Retinoid dermatitis.
Others:
- Vitamin C: Antioxidant, tyrosinase inhibitor.
- Niacinamide: Inhibits melanosome transfer.

⭐ Hydroquinone's most feared long-term side effect is exogenous ochronosis, a blue-black discoloration.

Feature	Hydroquinone	Azelaic Acid	Topical Retinoids
MOA	Tyrosinase inhibitor, melanocytotoxic	Tyrosinase inhibitor, anti-inflammatory, comedolytic	↑ Cell turnover, ↓ melanosome transfer
Key Indications	Melasma, Post-Inflammatory Hyperpigmentation (PIH)	Melasma, acne, rosacea	Melasma, acne, photoaging
Common SEs	Irritation, ochronosis (long-term)	Mild irritation	Retinoid dermatitis
Pregnancy Safety	Avoid	Safe	Avoid

Agents for Pigmentary Disorders - Color Creators

Focus: Vitiligo Management

Vitiligo on hands

Topical Corticosteroids:
- MOA: Immunosuppressive, anti-inflammatory.
- Potency: Mid (trunk/limbs), Low (face/intertriginous).
- SEs: Skin atrophy, telangiectasias, striae.
Topical Calcineurin Inhibitors (TCIs): (Tacrolimus, Pimecrolimus)
- MOA: Inhibit calcineurin → ↓T-cell activation & cytokine release.
- Use: Preferred for sensitive areas (face, eyelids, flexures) due to no atrophy risk.
⭐ Tacrolimus ointment is preferred for facial vitiligo due to lower risk of skin atrophy compared to topical corticosteroids.
Psoralens + UVA (PUVA): (Oral/Topical 8-Methoxypsoralen (8-MOP), Trioxsalen)
- MOA: Intercalate with DNA, form photoadducts with UVA → stimulate melanocytes.
- SEs: Phototoxic reactions, nausea (oral), ↑skin cancer risk (long-term).
Narrowband UVB (NB-UVB):
- Wavelength: 311-313 nm.
- Commonly preferred phototherapy; better safety profile than PUVA.

High‑Yield Points - ⚡ Biggest Takeaways

Hydroquinone: Tyrosinase inhibitor for hyperpigmentation; risk of ochronosis.

Tretinoin: Promotes epidermal turnover, treats melasma and photoaging.

Azelaic acid: Tyrosinase inhibitor & melanocytotoxic; for melasma, post-inflammatory hyperpigmentation (PIH).

Methoxsalen (Psoralen) + UVA (PUVA): For vitiligo repigmentation; stimulates melanocytes.

Monobenzone: Irreversible depigmenting agent for extensive vitiligo.

Topical Calcineurin Inhibitors (Tacrolimus): Steroid-sparing for vitiligo, especially facial.

Tranexamic acid: Oral/topical for melasma; inhibits plasmin-induced melanogenesis.

Continue reading on Oncourse

CONTINUE READING — FREE

or get the app

App Store|Google Play